Bristol-Myers Squibb CompanyBristol-Myers Squibb CompanyBristol-Myers Squibb Company

Bristol-Myers Squibb Company

No trades
Buy BMY

Key facts today

Bristol-Myers Squibb and 2Seventy Bio share equally in all profits and losses related to the development, manufacture, and commercialization of Abecma (idecabtagene vicleucel) in the U.S.
Bristol-Myers Squibb Co. experienced a stock increase of 3.3% during the trading session.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪106.76 B‬USD
−3.25USD
‪8.03 B‬USD
‪45.01 B‬USD
‪2.03 B‬
Beta (1Y)
0.06
Employees (FY)
‪34.1 K‬
Change (1Y)
−200 −0.58%
Revenue / Employee (1Y)
‪1.32 M‬USD
Net income / Employee (1Y)
‪235.34 K‬USD

About Bristol-Myers Squibb Company


CEO
Christopher S. Boerner
Headquarters
Princeton
Website
Founded
1933
FIGI
BBG000DQLV23
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
C
BMY4036425
Celgene Corporation 5.25% 15-AUG-2043
Yield to maturity
6.45%
Maturity date
Aug 15, 2043
BMY.GC
Bristol-Myers Squibb Company 6.875% 01-AUG-2097
Yield to maturity
6.02%
Maturity date
Aug 1, 2097
C
BMY4275603
Celgene Corporation 5.0% 15-AUG-2045
Yield to maturity
5.94%
Maturity date
Aug 15, 2045
C
BMY3685700
Celgene Corporation 5.7% 15-OCT-2040
Yield to maturity
5.92%
Maturity date
Oct 15, 2040
US110122EC8
BRIST.MYERS 23/63
Yield to maturity
5.80%
Maturity date
Nov 15, 2063
C
BMY4560589
Celgene Corporation 4.35% 15-NOV-2047
Yield to maturity
5.79%
Maturity date
Nov 15, 2047
C
BMY4597874
Celgene Corporation 4.55% 20-FEB-2048
Yield to maturity
5.67%
Maturity date
Feb 20, 2048
US110122EB0
BRIST.MYERS 23/53
Yield to maturity
5.64%
Maturity date
Nov 15, 2053
US110122EL8
BRIST.MYERS 24/64
Yield to maturity
5.63%
Maturity date
Feb 22, 2064
US110122EK0
BRIST.MYERS 24/54
Yield to maturity
5.51%
Maturity date
Feb 22, 2054
BMY5754772
Bristol-Myers Squibb Company FRN 20-FEB-2026
Yield to maturity
5.46%
Maturity date
Feb 20, 2026

Explore more bonds 

Frequently Asked Questions


The current price of BMY is 55.77 USD — it has increased by 5.91% in the past 24 hours. Watch Bristol-Myers Squibb Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Bristol-Myers Squibb Company stocks are traded under the ticker BMY.
BMY stock has risen by 5.43% compared to the previous week, the month change is a 7.35% rise, over the last year Bristol-Myers Squibb Company has showed a 7.54% increase.
We've gathered analysts' opinions on Bristol-Myers Squibb Company future price: according to them, BMY price has a max estimate of 62.00 USD and a min estimate of 37.00 USD. Watch BMY chart and read a more detailed Bristol-Myers Squibb Company stock forecast: see what analysts think of Bristol-Myers Squibb Company and suggest that you do with its stocks.
BMY reached its all-time high on Dec 1, 2022 with the price of 81.44 USD, and its all-time low was 0.91 USD and was reached on Oct 4, 1974. View more price dynamics on BMY chart.
See other stocks reaching their highest and lowest prices.
BMY stock is 6.61% volatile and has beta coefficient of 0.06. Track Bristol-Myers Squibb Company stock price on the chart and check out the list of the most volatile stocks — is Bristol-Myers Squibb Company there?
Today Bristol-Myers Squibb Company has the market capitalization of ‪106.76 B‬, it has decreased by −0.49% over the last week.
Yes, you can track Bristol-Myers Squibb Company financials in yearly and quarterly reports right on TradingView.
Bristol-Myers Squibb Company is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
BMY earnings for the last quarter are 1.80 USD per share, whereas the estimation was 1.49 USD resulting in a 20.47% surprise. The estimated earnings for the next quarter are 1.52 USD per share. See more details about Bristol-Myers Squibb Company earnings.
Bristol-Myers Squibb Company revenue for the last quarter amounts to ‪11.89 B‬ USD, despite the estimated figure of ‪11.26 B‬ USD. In the next quarter, revenue is expected to reach ‪11.48 B‬ USD.
BMY net income for the last quarter is ‪1.68 B‬ USD, while the quarter before that showed ‪−11.91 B‬ USD of net income which accounts for 114.10% change. Track more Bristol-Myers Squibb Company financial stats to get the full picture.
Yes, BMY dividends are paid quarterly. The last dividend per share was 0.60 USD. As of today, Dividend Yield (TTM)% is 4.50%. Tracking Bristol-Myers Squibb Company dividends might help you take more informed decisions.
Bristol-Myers Squibb Company dividend yield was 4.50% in 2023, and payout ratio reached 59.82%. The year before the numbers were 3.04% and 74.28% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 31, 2024, the company has ‪34.10 K‬ employees. See our rating of the largest employees — is Bristol-Myers Squibb Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bristol-Myers Squibb Company EBITDA is ‪18.20 B‬ USD, and current EBITDA margin is 40.62%. See more stats in Bristol-Myers Squibb Company financial statements.
Like other stocks, BMY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bristol-Myers Squibb Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bristol-Myers Squibb Company technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bristol-Myers Squibb Company stock shows the buy signal. See more of Bristol-Myers Squibb Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.